Antibodies to M-type phospholipase receptor and  immunological remission in treatment-resistant and relapsing membranous nephropathy

The report by van de Logt and colleagues1 adds to the expanding literature on the utility of measurement of antibodies against M-type phospholipase A2 receptor (aPLA2R) in diverse clinical circumstances in management of patients with membranous nephropathy. They show that rituximab is less effective than cyclophosphamide in effecting reduction in aPLA2R levels (immunological response), and that baseline antibody titers predict response to treatment, whether with rituximab or cyclic cyclophosphamide-glucocorticoid (cCTX-GC).
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Letter to the Editor Source Type: research